{"created":"2024-05-23T02:25:47.517510+00:00","id":2002605,"links":{},"metadata":{"_buckets":{"deposit":"a8162603-4fa1-4aa5-a6d4-3552a1963290"},"_deposit":{"created_by":7,"id":"2002605","owners":[7],"pid":{"revision_id":0,"type":"depid","value":"2002605"},"status":"published"},"_oai":{"id":"oai:jair.repo.nii.ac.jp:02002605","sets":["1616224532673:1708403533383:1709527609563:1709529608300"]},"author_link":[],"item_10006_alternative_title_1":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_alternative_title":"(SGLT2阻害薬トホグリフロジン単回投与による内因性糖産生増加には、血糖値の低下が必要である)","subitem_alternative_title_language":"ja"}]},"item_10006_date_granted_11":{"attribute_name":"学位授与年月日","attribute_value_mlt":[{"subitem_dategranted":"2021-03-20"}]},"item_10006_degree_grantor_9":{"attribute_name":"item_10006_degree_grantor_9","attribute_value_mlt":[{"subitem_degreegrantor":[{"subitem_degreegrantor_language":"ja","subitem_degreegrantor_name":"順天堂大学"}],"subitem_degreegrantor_identifier":[{"subitem_degreegrantor_identifier_name":"32620","subitem_degreegrantor_identifier_scheme":"kakenhi"}]}]},"item_10006_degree_name_8":{"attribute_name":"学位名","attribute_value_mlt":[{"subitem_degreename":"博士（医学）","subitem_degreename_language":"ja"}]},"item_10006_description_10":{"attribute_name":"学位授与年度","attribute_value_mlt":[{"subitem_description":"2020年度","subitem_description_language":"ja","subitem_description_type":"Other"}]},"item_10006_dissertation_number_12":{"attribute_name":"dissertation_number","attribute_value_mlt":[{"subitem_dissertationnumber":"甲第2336号"}]},"item_10006_relation_15":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_type":"isVersionOf","subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1111/dom.14312","subitem_relation_type_select":"DOI"}}]},"item_10006_rights_13":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"This is the peer reviewed version of the following article: [Yamasaki N, Tamura Y, Kaga H, Sato M, Kiya M, Kadowaki S, Suzuki R, Furukawa Y, Sugimoto D, Funayama T, Someya Y, Kakehi S, Nojiri S, Satoh H, Kawamori R, Watada H. A decrease in plasma glucose levels is required for increased endogenous glucose production with a single administration of a sodium-glucose co-transporter-2 inhibitor tofogliflozin. Diabetes Obes Metab. 2021 May;23(5):1092-1100.], which has been published in final form at [https://doi.org/10.1111/dom.14312]. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Use of Self-Archived Versions.","subitem_rights_language":"en"}]},"item_10006_version_type_18":{"attribute_name":"出版タイプ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_ab4af688f83e57aa","subitem_version_type":"AM"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"open access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_abf2"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"山﨑, 望","creatorNameLang":"ja"},{"creatorName":"ヤマサキ, ノゾム","creatorNameLang":"ja-Kana"}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"MDK2336-sinyou.pdf","filesize":[{"value":"209.9 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"審査結果の要旨","objectType":"other","url":"https://jair.repo.nii.ac.jp/record/2002605/files/MDK2336-sinyou.pdf"},"version_id":"c84573cf-4b54-4ab3-8fcb-854cf72243a9"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"MDK2336-ronyou.pdf","filesize":[{"value":"130.7 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"論文内容の要旨","objectType":"abstract","url":"https://jair.repo.nii.ac.jp/record/2002605/files/MDK2336-ronyou.pdf"},"version_id":"0be046dd-aca4-4a22-8cb0-5f71bd041c17"},{"accessrole":"open_access","date":[{"dateType":"Available","dateValue":"2021-03-20"}],"displaytype":"detail","filename":"MDK2336-zenbunps.pdf","filesize":[{"value":"802.6 KB"}],"format":"application/pdf","mimetype":"application/pdf","url":{"label":"全文【著者最終稿】","objectType":"fulltext","url":"https://jair.repo.nii.ac.jp/record/2002605/files/MDK2336-zenbunps.pdf"},"version_id":"2a5e69c6-f78d-410e-99e5-82fbcebd8ced"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"item_resource_type","attribute_value_mlt":[{"resourcetype":"doctoral thesis","resourceuri":"http://purl.org/coar/resource_type/c_db06"}]},"item_title":"A decrease in plasma glucose levels is required for increased EGP with a single administration of an SGLT2 inhibitor tofogliflozin","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"A decrease in plasma glucose levels is required for increased EGP with a single administration of an SGLT2 inhibitor tofogliflozin","subitem_title_language":"en"}]},"item_type_id":"40001","owner":"7","path":["1709529608300"],"pubdate":{"attribute_name":"PubDate","attribute_value":"2021-03-20"},"publish_date":"2021-03-20","publish_status":"0","recid":"2002605","relation_version_is_last":true,"title":["A decrease in plasma glucose levels is required for increased EGP with a single administration of an SGLT2 inhibitor tofogliflozin"],"weko_creator_id":"7","weko_shared_id":-1},"updated":"2024-11-27T00:04:40.424285+00:00"}